Go further than FEV1 and FVC – Mechanistic Biomarkers for Lung Disease

Posted on: October 11, 2022

This is an archived edition of our email newsletter.

It’s Not Just Support. It’s Solutions.

A Case for Letting Endotype Lead the Way in Drug Development…

Neutrophilic VS Eosinophilic

The molecular mechanisms that drive chronic lung disease are heterogenetic. To evolve past a “one drug fits all approach”, toward a more individualized and precision approach, pharmaceutical companies are focusing on drugs that can address each etiology within a disease. These subtypes of mechanistic drivers or pathobiology, endotypes, have come to the forefront in drug design. An endotype approach is therefore important for selecting targets for drug development and deployment.

COPD, bronchiectasis, and asthma are typically endotyped as eosinophilic or neutrophilic
Neutrophilic driven disease is indicated by high activity of neutrophil proteases, neutrophil elastase (NE), or proteinase 3 (PR3)
Neutrophil elastase activity measurement offers a way to better select targets for drug development aimed at neutrophil-specific pathways

DiaPharma offers assays from ProAxsis using ProteaseTag™ technology:

Neutrophil Elastase (NE) Activity Immunoassay – quantitative 96-well kit
Proteinase 3 (PR3) Immunoassay – quantitative 96-well kit
NEATstik Neutrophil Elastase – semi-quantitative lateral flow kit

For research use only. Not for use in diagnostic procedures.

Learn more about DiaPharma’s complimentary portfolio of products for pulmonary research

It’s Not Just Support. It’s Solutions.

Celebrating 25 years of scientific expertise,
with support just a call or click away.

DiaPharma Group, Inc. 8948 Beckett Rd, West Chester, OH 45069

Technical Support: 1.800.447.3846

ML-00-00970Rev01